SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
23 Outubro 2023 - 8:45AM
SEED Therapeutics (SEED), an innovative global biotech company
focused on engineering “molecular glues” and harnessing its
targeted protein degradation (TPD) platform to attack previously
undruggable targets, has appointed eminent international lawyer
Ko-Yung Tung to its Board of Directors. SEED is a
subsidiary of BeyondSpring (NASDAQ: BYSI), a global clinical-stage
biopharmaceutical company developing innovative therapies to
improve clinical outcomes for patients with high unmet medical
needs.
Mr. Tung has served as a director and strategic
advisor to leading international corporations and advisory
councils, including Eisai Co., Ltd., Hawaiian Airlines, and Kajima
Corporation. Mr. Tung formerly served as Senior Vice President and
General Counsel of the World Bank, Secretary General of the
International Centre of the Settlement of Investment Disputes
(ICSID), senior partner of O’Melveny & Myers, and Senior
Counsellor at Morrison & Foerster.
“Ko-Yung brings 50 years’ experience in
corporate governance, international investment, law, economic
development, and international business to SEED’s Board. His
joining is timely as SEED addresses domestic and international
opportunities to translate its TPD technology to new lead agents
ready for regulatory filings in advance of clinical testing.
Ko-Yung will extend his ongoing advice to the SEED Board and
Management on navigating increasingly complex legal, governance,
and geopolitical issues as we pursue our mission of introducing
SEED’s TPD technology and platform to improve the quality of life
for patients across the globe,” said Dr. Lan Huang, Chairman and
Chief Executive Officer of BeyondSpring, and Chairman, CEO and
Co-Founder of SEED.
Mr. Tung currently serves as a board member of
the Global Health Innovative Technology Fund (GHIT) in Japan with
funding from the Gates Foundation, the Japanese government,
Wellcome Trust, and large Japan pharmaceutical firms, including
Takeda, Astellas, and Eisai. GHIT makes grants to international
development partners in the field of Neglected Tropical Diseases.
While at the World Bank, Mr. Tung provided legal advice in the
establishment of the Global Fund for AIDS, Malaria and
Tuberculosis. He has been at the lead of cross-border public
policy, including as a member of the Trilateral Commission, U.S.
Presidential Commission on United States Pacific Trade and
Investment Policy, and Chairman of the Board of Governors of the
East-West Center. He is also a member of the Council on Foreign
Relations and has been associated with the American Society of
International Law, International Bar Association, and Bar of the
City of New York. As a distinguished scholar, Mr. Tung has taught
at Harvard Law School, Yale Law School, and NYU Law School for many
years. Mr. Tung received his education at Harvard College (B.A. in
physics, magna cum laude), Harvard Law School (J.D.), and
University of Tokyo, Faculty of Law.
“I have always been committed to helping people
with unmet medical problems, whether in new drugs, affordability,
or public policy. I am honored to be working closely with SEED’s
Scientific Co-Founders and our team of seasoned scientists and
development experts as SEED transforms its groundbreaking TPD
platform into a portfolio of approved drugs to address unmet
medical needs. It is inspiring to see SEED’s unwavering commitment
and leadership to be TPD trailblazers and to raise the quality of
life for patients around the world,” said Mr. Tung.
About SEED TherapeuticsSEED
Therapeutics is an innovative biotech company focusing on
harnessing and engineering “molecular glues” and targeted protein
degradation (TPD) to attack previously undruggable targets. Backed
by a comprehensive intellectual property portfolio, SEED
Therapeutics' mission is to positively impact human health by
creating novel protein degradation therapeutics to treat various
severe diseases that currently have limited treatment options for
patients and their families. Through ongoing collaborations with
world-leading academic experts in the field, SEED Therapeutics is
developing a growing pipeline of novel drug candidates on a path to
potential clinical and commercial success. SEED has an initial
R&D collaboration and investment from Eli Lilly. With today’s
announcement, SEED’s Board of Directors is composed of SEED
Chairman, CEO and Co-Founder Dr. Lan Huang, PhD, an ubiquitin
ligase expert, biotech entrepreneur, and Chairman, CEO and
Co-Founder of BeyondSpring; Dr. James Tonra, PhD, seasoned
translational science leader and SEED President and Chief
Scientific Officer; Dr. Linus Lin, PhD, drug discovery and
development expert and global head of Eli Lilly Chorus; Jackson
Tai, corporate governance, finance, and risk expert and recently
retired Eli Lilly director; and Ko-Yung Tung, eminent international
lawyer, cross-border strategic advisor, and former World Bank
General Counsel. Learn more by visiting
https://seedtherapeutics.com/.
About BeyondSpringBeyondSpring
(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company
focusing on developing innovative therapies to improve clinical
outcomes for patients with high unmet medical needs. The Company is
advancing its first-in-class lead asset, Plinabulin, as a direct
anti-cancer agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform for novel drug
development in oncology, neurodegeneration, and virology. Learn
more by visiting https://beyondspringpharma.com, and follow us on
LinkedIn and Twitter.
Investor Contact:IR@beyondspringpharma.com
Media Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024